article thumbnail

The Road Ahead for Private Equity: Reflections and Predictions

JD Supra: Mergers

The year 2023 will be remembered as a challenging one for private equity (PE), with complexities to navigate on many fronts. Although overall transaction volume was significantly down, private equity funds still found. By: Akin Gump Strauss Hauer & Feld LLP

article thumbnail

Antitrust scrutiny of private equity deals intensifies

JD Supra: Mergers

Traditionally, private equity firms were seen as benign investors from an antitrust perspective. This is changing. In the past 12 months, PE-funded acquisitions have faced progressively more rigorous scrutiny by antitrust authorities. By: Allen & Overy LLP

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

California’s AB 3129 Continues National Trend of Scrutinizing Private Equity Investments in the Health Care Industry

JD Supra: Mergers

The California legislature is considering a bill that could severely impact the ability for private equity companies and hedge funds to operate in the California health care industry. By: Polsinelli

article thumbnail

2024 Healthcare Private Equity Outlook & Trends

JD Supra: Mergers

As we begin 2024, we have highlighted the issues and trends that private equity (PE) investors should consider when evaluating transactions in the healthcare sector. W ith various headwinds resulting in down volume in 2023, buyers and sellers alike find themselves asking whether 2024 will see a rebound in deal activity.

article thumbnail

Private Equity in Healthcare: Increased Scrutiny from FTC, DOJ, and HHS

JD Supra: Mergers

Private equity acquisitions in healthcare will likely face increased scrutiny from multiple federal departments, as well as from state antitrust enforcement officials. By: Mayer Brown

article thumbnail

FTC is Targeting Private Equity Acquisitions in Healthcare - Is Your Industry Next?

JD Supra: Mergers

On March 5, the FTC convened a workshop with regulators, academics and stakeholders to discuss the impact of private equity in the healthcare market. The workshop reflects the FTC and DOJ Antitrust Division’s recent focus on private equity and serial roll-up transactions more broadly as targets for antitrust enforcement.

article thumbnail

Antitrust Enforcers Amp Up Focus on Private Equity Acquisitions in the Health Care Market

JD Supra: Mergers

Private equity is squarely in the cross hairs of regulators; the Department of Justice Antitrust Division, the Federal Trade Commission, and the U.S. Department of Health and Human Services recently announced the launch of a joint inquiry into private equity ownership in the health care field. By: Ballard Spahr LLP